Vaccine manufacturer Bavarian Nordic has agreed to be acquired by a consortium led by private equity firms Nordic Capital and Permira in an all-cash deal valued at approximately $3 billion. The offer represents a 21% premium over the company’s last stock price before takeover rumors. Bavarian Nordic, known for its diverse vaccine portfolio including mpox vaccines approved in the EU and US, plans to continue investing in pipeline expansion and acquisitions under private ownership. The board unanimously supports the transaction, assured by fairness opinions from leading financial advisors.